metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) | |
non squamous - mNSCLC - L2 - all population | |
anti-PD-(L)1 | |
nivolumab based treatment | |
nivolumab alone | CheckMate 057 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -